Canaccord Genuity Group Issues Pessimistic Forecast for Sage Therapeutics (NASDAQ:SAGE) Stock Price

Sage Therapeutics (NASDAQ:SAGE – Get Free Report) had its target price reduced by equities researchers at Canaccord Genuity Group from $9.00 to $8.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm presently has a “hold” rating on the biopharmaceutical company’s stock. Canaccord Genuity Group’s target price would suggest a potential upside […]